The pharmaceutical company PJSC SIC Borshchahivskiy Chemical Pharmaceutical Plant (BCPP, Kyiv) increased its net profit by almost 17% in 2024 compared to 2023, to UAH 273.402 million.
As the company reported in the information disclosure system of the National Securities and Stock Market Commission (NSSMC), the shareholders will consider the company’s performance results at a meeting on April 30.
The shareholders will consider the allocation of UAH 40.369 million from the net profit for 2024 to pay dividends.
In addition, the agenda includes the termination of the powers of the Supervisory Board (SB) members Tetyana Artemenko, Mykola Bezpalko, Oleg Goloborodko (all three are ultimate beneficial owners) and Dmytro Guz. The new composition of the SB will be proposed by shareholders and is not currently on the agenda of the meeting.
As reported, BCPP’s net profit in 2023 increased by 3.38% compared to 2022 to UAH 262.863 million.
As of the first quarter of 2023, 31.8% of BCPP shares were owned by the pharmaceutical company PrJSC “Pharmaceutical Firm ‘Darnitsa’ (Kyiv). Other shareholders of the company were Beldor Group (21.26%) and Lenik Group (20.32%).
According to the Opendatabot system, the ultimate beneficiaries of BCPP are Hlib Zahoriy, the beneficiary of the Darnitsa Pharmaceutical Company, Yevhen Sova, Tetiana Artemenko, Mykola Bezpalko and Oleh Holoborodko.
